Medicare CAR-T Payment Policy Walks Line Between Innovation and Cost Concerns
Executive Summary
CMS proposes new DRG with higher average payment rate for CAR-T therapy but signals new technology add-on payments will no longer be awarded to supplement reimbursement.
You may also be interested in...
Medicare And CAR-Ts: Breyanzi Denied Add-On Payments But Tecartus, Abecma Approved
CMS shows willingness to continue approving new technology add-on payments for CAR-T treatments despite suggestions they are no longer needed.
As CAR-Ts Proliferate, CMS Seeks To Reserve Medicare Add-On Payments For ‘New’ Therapies
Products from Bristol-Myers Squibb, Gilead and J&J might be eligible for supplemental reimbursement under hospital payment proposed rule that could help promote uptake.
BMS/Bluebird Ready Abecma, First BCMA-Targeting CAR-T, For Initial Patients
Idecabtagene vicleucel for fifth-line multiple myeloma lags GSK’s BCMA-targeting ADC Blenrep, but it is months ahead of J&J/Legend’s CAR-T. Abecma is BMS’s second CAR-T approval this year.